Pierre-Joseph Pelletier
1788-1842 · Franzose · Pharmakologie
Französischer Chemiker, dessen Isolierung von Pflanzenalkaloiden (Chinin, Strychnin, Koffein, Brucin) die Methodik der Reinstoffextraktion begründete, die später von Haycraft und Jacoby angewandt wurde, um Hirudin aus den Speicheldrüsen medizinischer Blutegel zu gewinnen.
Profil
- Lebensjahre
- 1788-1842
- Nationalität
- French
- Epoche
- 19. Jahrhundert
- Hauptfachgebiet
- Pharmakologie
Institutionelle Zugehörigkeiten
- École de pharmacie de Paris (Professor and later Director)
- Académie des sciences, Paris (member, 1840)
- Pelletier-Caventou quinine manufactory, Paris
Wichtige Beiträge
- Co-isolated quinine from Cinchona bark with Joseph Bienaimé Caventou in 1820 — a milestone in the chemistry of natural products and the foundation of modern antimalarial therapy.
- Co-isolated strychnine, brucine, veratrine, and caffeine in the early 1820s, establishing the conceptual category of the alkaloid as a class of nitrogen-containing plant secondary metabolites with potent physiological action.
- Developed the methodological template — solvent extraction, salt formation, recrystallization — that became the standard approach to isolating active principles from biological tissues throughout the nineteenth century.
- Co-founded the first industrial-scale quinine manufactory in Paris, demonstrating that pure-compound natural-product chemistry could supply therapy at clinical scale.
- Served as professor of natural history of medicines at the École de pharmacie de Paris and exercised wide influence on the next generation of French chemists.
Bedeutung für die Hirudotherapie
Pierre-Joseph Pelletier never worked on leeches and never published on hirudin — yet his methodological contributions are foundational to the entire molecular era of hirudotherapy. The technique by which John Berry Haycraft isolated hirudin in 1884 (saline perfusion, protein precipitation, dialysis, lyophilization) and by which Karl Jacoby industrialized hirudin extraction in 1902 (large-scale tissue maceration, salt fractionation, repeated recrystallization) descends directly from the natural-product chemistry that Pelletier and his collaborator Joseph Caventou pioneered in Paris between roughly 1817 and 1825. Without this methodological tradition, the leech salivary gland would have remained a black box of unspecified bioactive secretions. The specific intellectual leap that Pelletier embodied was the move from describing the actions of a crude botanical or biological preparation (cinchona bark, opium, leech saliva) to isolating the single chemical principle responsible for those actions. Before Pelletier, pharmacology was largely the study of mixtures; after Pelletier, it became the study of pure compounds with definable molecular structure. This conceptual reorientation is precisely what made hirudin meaningful as a research subject: Haycraft did not merely show that leech saliva inhibited clotting (a fact known anecdotally for centuries), he isolated a discrete protein that did so reproducibly and which could in principle be characterized further. The American Society of Hirudotherapy includes Pelletier in its biographical registry as the patron of the natural-product chemistry tradition from which modern hirudin and leech-derived drug discovery descend. Every recombinant hirudin product on the market today, every Factor Xa inhibitor descended from antistasin or ghilanten, every destabilase research program, traces its methodological lineage through Markwardt's 1957 purification, through Jacoby's 1902 extraction, through Haycraft's 1884 isolation, back to Pelletier and Caventou's quinine in 1820. He is the indirect intellectual ancestor of the entire leech-pharmacology field.
Wichtige Publikationen
- Recherches chimiques sur les quinquinas (with J. B. Caventou) · Annales de chimie et de physique (1820)
- Sur un nouvel alcali végétal (la strychnine) trouvé dans la fève de Saint-Ignace, la noix vomique, etc. · Annales de chimie et de physique (1819)
- Note sur la caféine · Journal de pharmacie (1821)
Externe Ressourcen
Beeinflusste Forschung
Verbindungen und Forschungsbereiche, die auf die Beiträge dieser Persönlichkeit zurückgehen:
Verwandte Persönlichkeiten
John Berry Haycraft
1857-1922 · Brite (Schotte)
Edinburgh-Physiologe, der 1884 Hirudin entdeckte und die moderne Molekularpharmakologie des Blutegelspeichels begründete.
Fritz Markwardt
1924-2011 · Deutscher (Ostdeutscher / DDR)
Greifswalder Pharmakologe, der 1957 Hirudin bis zur Homogenität reinigte, seinen Mechanismus charakterisierte und die gesamte wissenschaftliche Grundlage für die moderne Arzneimittelklasse der direkten Thrombin-Inhibitoren legte.
John W. Fenton II
1937-2007 · Amerikaner
Biochemiker am Albany Medical College, dessen Aufreinigung und Charakterisierung von rekombinantem Hirudin in den späten 1980er Jahren die Entwicklung von Lepirudin (Refludan) durch Hoechst Marion Roussel / Behringwerke ermöglichte — den ersten FDA-zugelassenen direkten Thrombin-Inhibitor.
John M. Maraganore
1956- · Amerikaner
Gründer von Biogen / The Medicines Company, der Bivalirudin (Angiomax) entwarf — das rational designte synthetische Hirudin-Analogon, das zum Standard-Direktthrombin-Inhibitor für perkutane Koronarinterventionen wurde.